Bausch Health Companies Inc. is a multinational pharmaceutical company that develops, manufactures, and markets a diverse portfolio of branded and generic drugs, over-the-counter (OTC) products, and medical devices. The company's operations are organized into several key segments: Salix, which focuses on gastroenterology and hepatology products (notably Xifaxan); International, which offers branded generics and OTC products across Europe, the Middle East, Africa, Latin America, and Asia Pacific; Solta Medical, which provides medical aesthetics devices; Diversified, which includes neurology, dermatology, and dentistry products; and Bausch + Lomb, a premier eye health business in which Bausch Health retains a majority ownership stake following its 2022 IPO. Bausch Health operates in approximately 90 countries, with a significant commercial footprint in the United States and Canada. The company's business model relies on a combination of internal research and development, strategic acquisitions, and lifecycle management of its established product portfolio to drive revenue and address unmet medical needs across its therapeutic focus areas.
